Nanobiotix
Nanobiotix is a late-stage clinical biotechnology company that develops physics-based nanotherapeutics to treat cancer and other diseases. Its lead product candidate, NBTXR3, is a radioenhancer designed to increase the radiotherapy dose absorbed by tumor cells while protecting surrounding healthy tissue. The company is currently evaluating this technology in clinical trials for head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.
Biotechnology
Oncology
Healthtech
Funding summary
- Total raised
- €12.7M
- Funding rounds
- 2
Investors in Nanobiotix
Investors on record for Nanobiotix. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Nanobiotix?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors